Connect with our team to translate biomarker insights into strategies that can withstand scientific scrutiny and support real clinical impact.
By submitting this form, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may unsubscribe from these communications by following the unsubscribe link or the instructions provided in the communication we send. The information you submit is governed by our Privacy Notice and our website Terms of Use.
Contact Information
Promising biomarker signals are not enough.
To support a clinical program, a biomarker must be rigorously validated, reproducible, and clinically meaningful.
We partner with you to evaluate and strengthen biomarker strategies, so they can support confident clinical decisions.
A biomarker hypothesis becomes valuable only when it can withstand scientific scrutiny and demonstrate clear clinical relevance.
We help you translate early signals into biomarker strategies robust enough to support trial design and patient selection.
We combine deep scientific expertise, advanced profiling platforms, and large-scale data to determine whether your biomarker can reliably support a clinical program.
A biomarker must demonstrate consistent and reproducible signals across technologies and sample types.
We help you:
So your biomarker is supported by reliable, reproducible data
Even strong signals can fail if they are not clinically meaningful.
So your biomarker strategy is grounded in meaningful clinical insight
Biomarker decisions require deep scientific expertise and proven experience.
So your strategy is informed by proven scientific rigor and real-world experience
Our biomarker evaluation work draws on a comprehensive suite of genomic technologies, validated assays, and development capabilities.
Core diagnostic and assay capabilities include:
Development and validation capabilities:
Supporting biomarker strategy across development
These capabilities enable biomarker strategies to be evaluated, validated, and refined across technologies, sample types, and clinical settings.
Evaluating a biomarker requires more than detecting a signal. It requires demonstrating that the signal is robust, reproducible, and reliable enough to support regulatory submissions and clinical decisions.
We have deep experience developing and validating biomarker assays across multiple platforms, ensuring biomarker strategies are not only scientifically sound, but also capable of supporting downstream clinical development and regulatory requirements.
Our approach includes:
Before advancing into clinical development, you need to know your biomarker can support the decisions ahead, so you can move forward with clarity and reduce downstream risk
We help ensure your biomarker strategy is:
Once your biomarker strategy is established, the next decisions determine whether your program can demonstrate real clinical impact.